Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2022-10-13
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 400
- Registration Number
- NCT04944368
- Locations
- 🇮🇷
Espinas Palace Hotel, Tehran, Iran, Islamic Republic of
Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran
Completed
- Conditions
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 368
- Registration Number
- NCT04928313
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
Completed
- Conditions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 654
- Registration Number
- NCT04460079
Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 40
- Registration Number
- NCT03614715
- Locations
- 🇫🇮
CRST Oy, Clinical Research Services Turku Itäinen Pitkäkatu 4 B, 3rd floor, Turku, Finland
Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 300
- Registration Number
- NCT03421119
Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 156
- Registration Number
- NCT03408639
- Locations
- 🇮🇷
Javad-al-Aemeh clinic, Kerman, Iran, Islamic Republic of
🇮🇷Hashemi Nezhad Hospital, Tehran, Iran, Islamic Republic of
🇮🇷Haj Ebrahimi dialysis center, Shiraz, Iran, Islamic Republic of
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 234
- Registration Number
- NCT03391934
- Locations
- 🇮🇷
Taleqani Hospital, Tehran, Iran, Islamic Republic of
A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 74
- Registration Number
- NCT03273192
- Locations
- 🇮🇷
Orchidpharmed PK/PD site, Tehran, Iran, Islamic Republic of
Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 30
- Registration Number
- NCT03223025
Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 136
- Registration Number
- NCT03172325
- Locations
- 🇮🇷
Alzahra Hospital, Isfahan, Iran, Islamic Republic of
🇮🇷Imam Reza Hospital (501 Artesh), Tehran, Iran, Islamic Republic of
🇮🇷Noor Medical Complex, Tabriz, Iran, Islamic Republic of
© Copyright 2024. All Rights Reserved by MedPath